Vaccination with Theratope (STn-KLH) as treatment for breast cancer.
Vaccination with Theratope (STn-KLH) as treatment for breast cancer.
复制标题
DOI：
10.1586/14760584.3.6.655
复制
发表时间：
2004-12-01
影响因子：
6.2
通讯作者：
Sandmaier, Brenda M
中科院分区：
文献类型：
--
作者：
Holmberg, Leona A;Sandmaier, Brenda M
癌症疫苗已被证明可以在实验室中刺激针对肿瘤相关抗原的抗体和细胞介导的免疫反应。然而，很少有癌症疫苗的临床研究显示出令人信服的临床反应。唾液酸-Tn是与MUC 1相关的碳水化合物。它是一种独特的肿瘤相关抗原，存在于许多腺癌，包括乳腺癌、卵巢癌、结直肠癌、胃癌和胰腺癌。因此，唾液酸-TN是增强患者免疫系统特异性对抗独特肿瘤相关抗原的理想候选物。癌症疫苗Theratope由Biomira公司开发。使用模拟人类癌症独特碳水化合物的合成唾液酸-Tn抗原。临床试验主要在乳腺癌患者中进行，这些试验在本简介中概述。
Cancer vaccines have demonstrated that they can stimulate antibody and cell-mediated immune responses against tumor-associated antigens in the laboratory. However, few clinical studies with cancer vaccines have demonstrated convincing clinical responses. Sialyl-Tn is a carbohydrate associated with MUC1. It is a unique tumor-associated antigen, present on many adenocarcinomas including breast, ovarian, colorectal, gastric and pancreatic. Consequently, Sialyl-TN is an ideal candidate for boosting the patient's immune system specifically against a unique tumor-associated antigen. The cancer vaccine Theratope was developed by Biomira, Inc. using a synthetic Sialyl-Tn antigen that emulates the unique carbohydrate on human cancer. Clinical trials have predominantly been carried out in breast cancer patients and these trials are outlined in this profile.